Immuneering Signs Supply Deal with Lilly to Test Atebimetinib Plus Olomorasib (IMRX:NASDAQ)

Immuneering signs supply deal with Lilly to test atebimetinib plus olomorasib (IMRX:NASDAQ)

Immuneering (IMRX) partners with Eli Lilly to test atebimetinib + olomorasib in a phase 2 trial targeting KRAS G12c-mutant lung cancer. Read more here.

Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, Aug. 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company committed to developing, manufacturing and commercializing high-quality medicines in oncology, cardiovascular and metabolic diseases, autoimmune, ophthalmology and other major therapeutic…

Innovent wins FDA nod, launches lung-cancer race

SAN FRANCISCO and SUZHOU, China, Aug. 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company committed to developing, manufacturing and commercializing high-quality medicines in oncology, cardiovascular and metabolic diseases, autoimmune, ophthalmology and other major therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational n…

First-in-Class Dual-Action Cancer Drug: Innovent's IBI363 Heads to Global Phase 3 Trial for Resistant Lung Cancer

Innovent's IBI363, a novel PD-1/IL-2α-bias therapy, receives FDA clearance for 600-patient global Phase 3 trial in squamous NSCLC. Study spans US, China, EU, UK, Japan comparing IBI363 vs docetaxel.